Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell®)
2007

Efficacy and Safety of Nicotinell Nicotine Lozenges

Sample size: 900 publication 10 minutes Evidence: high

Author Information

Author(s): Dautzenberg Bertrand, Nides Mitchell, Kienzler Jean-Luc, Callens Anne

Primary Institution: Groupe Hospitalier Pitié-Salpêtrière, Paris, France

Hypothesis

Increasing treatment options for smoking cessation will help more smokers find the support they need to quit.

Conclusion

Nicotinell lozenges demonstrate high nicotine bioavailability, excellent safety, and proven short-term efficacy for smoking cessation.

Supporting Evidence

  • The 1 mg Nicotinell lozenge is bioequivalent to 2 mg nicotine gum.
  • Significantly more subjects were continuously abstinent from smoking with active lozenges compared to placebo.
  • Nicotinell lozenges were found to be safe with mainly mild and reversible adverse events.

Takeaway

Nicotinell lozenges help people stop smoking by providing nicotine without the harmful effects of cigarettes, and they are safe to use.

Methodology

The study involved pharmacokinetic, safety, and efficacy trials comparing Nicotinell lozenges with nicotine gum in smokers.

Potential Biases

Potential bias due to funding from Novartis Consumer Health.

Limitations

The study did not provide specific behavioral counseling to participants.

Participant Demographics

Adult healthy smokers, aged ≥ 18 years, smoking at least 10 cigarettes per day.

Statistical Information

P-Value

0.03

Confidence Interval

[95% CI: 1.05–2.80]

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1472-6904-7-11

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication